Clinical Evidence of Interaction between Nutraceutical Supplementation
and Platinum-based Chemotherapy

Veronica      Cocetta; Mattia      Tinazzi; Isabella      Giacomini; Benedetta      Rosato; Eugenio      Ragazzi; Massimiliano      Berretta; Monica      Montopoli
Abstract

Platinum agents, which include cisplatin, oxaliplatin and carboplatin, are chemotherapeutic drugs that represent the first-line treatment for different types of solid tumors, such as ovarian, head and neck, testicular, and bladder cancers. Their beneficial effect is limited by the onset of drug resistance and severe toxicities, involving mainly ototoxicity, neurotoxicity and nephrotoxicity. Recent studies highlight the supplementation of herbal products, vitamins and minerals with antioxidant properties to prevent and protect from side effects. In particular, the introduction of nutraceuticals associated with chemotherapy has improved the patients’ quality of life. However, if from one side, complementary and alternative medicine ameliorates chemotherapeutics-induced toxicities, from the other side, it is important to take into consideration the possible interference with drug metabolism. This review aims to consider the current literature focusing on clinical trials that report an association between nutraceutical supplementation and platinum- based chemotherapy to prevent toxicities, highlighting both beneficial and side effects.
Keywords: Platinum agents, nutraceuticals, nutraceutical supplementation, chemotherapy, clinical evidence, toxicity, interaction.
[1]
Mayne, S.T.; Playdon, M.C.; Rock, C.L. Diet, nutrition, and cancer: Past, present and future. Nat. Rev. Clin. Oncol.,  2016, 13(8), 504-515.
 [http://dx.doi.org/10.1038/nrclinonc.2016.24] [PMID: 26951041]

[2]
Steck, S.E.; Murphy, E.A. Dietary patterns and cancer risk. Nat. Rev. Cancer,  2020, 20(2), 125-138.
 [http://dx.doi.org/10.1038/s41568-019-0227-4] [PMID: 31848467]

[3]
Cocetta, V.; Ragazzi, E.; Montopoli, M. Links between cancer metabolism and cisplatin resistance. Int. Rev. Cell Mol. Biol.,  2020, 354, 107-164.
 [http://dx.doi.org/10.1016/bs.ircmb.2020.01.005] [PMID: 32475471]

[4]
Giacomini, I.; Gianfanti, F.; Desbats, M.A.; Orso, G.; Berretta, M.; Prayer-Galetti, T.; Ragazzi, E.; Cocetta, V. Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy. Front. Oncol.,  2021, 11, 682911.
 [http://dx.doi.org/10.3389/fonc.2021.682911] [PMID: 34109128]

[5]
Zick, S.M.; Snyder, D.; Abrams, D.I. Pros and cons of dietary strategies popular among cancer patients. Oncology (Williston Park),  2018, 32(11), 542-547.
 [PMID: 30474102]

[6]
Tajan, M.; Vousden, K.H. Dietary approaches to cancer therapy. Cancer Cell,  2020, 37(6), 767-785.
 [http://dx.doi.org/10.1016/j.ccell.2020.04.005] [PMID: 32413275]

[7]
Catanzaro, D.; Gabbia, D.; Cocetta, V.; Biagi, M.; Ragazzi, E.; Montopoli, M.; Carrara, M. Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. Fitoterapia,  2018, 124, 42-48.
 [http://dx.doi.org/10.1016/j.fitote.2017.10.007] [PMID: 29031537]

[8]
Raffaghello, L.; Lee, C.; Safdie, F.M.; Wei, M.; Madia, F.; Bianchi, G.; Longo, V.D. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA,  2008, 105(24), 8215-8220.
 [http://dx.doi.org/10.1073/pnas.0708100105] [PMID: 18378900]

[9]
Csiszar, A.; Labinskyy, N.; Jimenez, R.; Pinto, J.T.; Ballabh, P.; Losonczy, G.; Pearson, K.J.; de Cabo, R.; Ungvari, Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: Role of circulating factors and SIRT1. Mech. Ageing Dev.,  2009, 130(8), 518-527.
 [http://dx.doi.org/10.1016/j.mad.2009.06.004] [PMID: 19549533]

[10]
Dorff, T.B.; Groshen, S.; Garcia, A.; Shah, M.; Tsao-Wei, D.; Pham, H.; Cheng, C-W.; Brandhorst, S.; Cohen, P.; Wei, M.; Longo, V.; Quinn, D.I. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer,  2016, 16(1), 360.
 [http://dx.doi.org/10.1186/s12885-016-2370-6] [PMID: 27282289]

[11]
Gunebakan, E.; Yalcin, E.; Dulger, E.C.; Yigitbasi, A.; Ates, N.; Caglayan, A.; Beker, M.C.; Sahin, K.; Korkaya, H.; Kilic, E. Short-Term diet restriction but not alternate day fasting prevents cisplatin-induced nephrotoxicity in mice. Biomedicines,  2020, 8(2), 23.
 [http://dx.doi.org/10.3390/biomedicines8020023] [PMID: 32028692]

[12]
Estrela, G.R.; Wasinski, F.; Batista, R.O.; Hiyane, M.I.; Felizardo, R.J.F.; Cunha, F.; de Almeida, D.C.; Malheiros, D.M.A.C.; Câmara, N.O.S.; Barros, C.C.; Bader, M.; Araujo, R.C. Caloric restriction is more efficient than physical exercise to protect from cisplatin nephrotoxicity via PPAR-Alpha activation. Front. Physiol.,  2017, 8, 116.
 [http://dx.doi.org/10.3389/fphys.2017.00116] [PMID: 28303105]

[13]
Smith, P.J.; Clavarino, A.; Long, J.; Steadman, K.J. Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks? Asia Pac. J. Clin. Oncol.,  2014, 10(1), 1-10.
 [http://dx.doi.org/10.1111/ajco.12115] [PMID: 23910177]

[14]
Henderson, J.W.; Donatelle, R.J. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern. Ther. Health Med.,  2004, 10(1), 52-57.
 [PMID: 14727500]

[15]
Zeller, T.; Muenstedt, K.; Stoll, C.; Schweder, J.; Senf, B.; Ruckhaeberle, E.; Becker, S.; Serve, H.; Huebner, J. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J. Cancer Res. Clin. Oncol.,  2013, 139(3), 357-365.
 [http://dx.doi.org/10.1007/s00432-012-1336-6] [PMID: 23099993]

[16]
Petersen, M.J.; Bergien, S.O.; Staerk, D. A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs. Phytother. Res.,  2021, 35(7), 3610-3631.
 [http://dx.doi.org/10.1002/ptr.7050] [PMID: 33624893]

[17]
Skovgaard, L.; Pedersen, I.K.; Verhoef, M. Exclusive use of alternative medicine as a positive choice: A qualitative study of treatment assumptions among people with multiple sclerosis in denmark. Int. J. MS Care,  2014, 16(3), 124-131.
 [http://dx.doi.org/10.7224/1537-2073.2013-010] [PMID: 25337054]

[18]
Dilruba, S.; Kalayda, G.V. Platinum-based drugs: Past, present and future. Cancer Chemother. Pharmacol.,  2016, 77(6), 1103-1124.
 [http://dx.doi.org/10.1007/s00280-016-2976-z] [PMID: 26886018]

[19]
Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene,  2012, 31(15), 1869-1883.
 [http://dx.doi.org/10.1038/onc.2011.384] [PMID: 21892204]

[20]
Fuertes, M.A.; Castilla, J.; Alonso, C.; Pérez, J.M. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem.,  2003, 10(3), 257-266.
 [http://dx.doi.org/10.2174/0929867033368484] [PMID: 12570712]

[21]
Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans.,  2010, 39(35), 8113-8127.
 [http://dx.doi.org/10.1039/c0dt00292e] [PMID: 20593091]

[22]
Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol.,  2014, 740, 364-378.
 [http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]

[23]
Canetta, R.; Rozencweig, M.; Carter, S.K. Carboplatin: The clinical spectrum to date. Cancer Treat. Rev.,  1985, 12(Suppl. A), 125-136.
 [http://dx.doi.org/10.1016/0305-7372(85)90027-1] [PMID: 3002623]

[24]
Raymond, E.; Chaney, S.G.; Taamma, A.; Cvitkovic, E. Oxaliplatin: A review of preclinical and clinical studies. Ann. Oncol.,  1998, 9(10), 1053-1071.
 [http://dx.doi.org/10.1023/A:1008213732429] [PMID: 9834817]

[25]
Zhang, S.; Lovejoy, K.S.; Shima, J.E.; Lagpacan, L.L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J.W.; Chen, X.; Lippard, S.J.; Giacomini, K.M. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res.,  2006, 66(17), 8847-8857.
 [http://dx.doi.org/10.1158/0008-5472.CAN-06-0769] [PMID: 16951202]

[26]
Culy, C.R.; Clemett, D.; Wiseman, L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs,  2000, 60(4), 895-924.
 [http://dx.doi.org/10.2165/00003495-200060040-00005] [PMID: 11085200]

[27]
Fang, C.Y.; Lou, D.Y.; Zhou, L.Q.; Wang, J.C.; Yang, B.; He, Q.J.; Wang, J.J.; Weng, Q.J. Natural products: Potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol. Sin.,  2021, 42(12), 1951-1969.
 [http://dx.doi.org/10.1038/s41401-021-00620-9] [PMID: 33750909]

[28]
Carocho, M.; Ferreira, I.C.F.R. A review on antioxidants, prooxidants and related controversy: Natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem. Toxicol.,  2013, 51, 15-25.
 [http://dx.doi.org/10.1016/j.fct.2012.09.021] [PMID: 23017782]

[29]
Warraich, U.E.; Hussain, F.; Kayani, H.U.R. Aging - Oxidative stress, antioxidants and computational modeling. Heliyon,  2020, 6(5), e04107.
 [http://dx.doi.org/10.1016/j.heliyon.2020.e04107] [PMID: 32509998]

[30]
Fernando, W.; Rupasinghe, H.P.V.; Hoskin, D.W. Dietary phytochemicals with anti-oxidant and pro-oxidant activities: A double-edged sword in relation to adjuvant chemotherapy and radiotherapy? Cancer Lett.,  2019, 452, 168-177.
 [http://dx.doi.org/10.1016/j.canlet.2019.03.022] [PMID: 30910593]

[31]
Stankovic, J.S.K.; Selakovic, D.; Mihailovic, V.; Rosic, G. Antioxidant supplementation in the treatment of neurotoxicity induced by platinum-based chemotherapeutics-a review. Int. J. Mol. Sci.,  2020, 21(20), 7753.
 [http://dx.doi.org/10.3390/ijms21207753] [PMID: 33092125]

[32]
Olszowy, M. What is responsible for antioxidant properties of polyphenolic compounds from plants? Plant Physiol. Biochem.,  2019, 144, 135-143.
 [http://dx.doi.org/10.1016/j.plaphy.2019.09.039] [PMID: 31563754]

[33]
Gröber, U.; Holzhauer, P.; Kisters, K.; Holick, M.F.; Adamietz, I.A. Micronutrients in oncological intervention. Nutrients,  2016, 8(3), 163.
 [http://dx.doi.org/10.3390/nu8030163] [PMID: 26985904]

[34]
Norman, H.A.; Butrum, R.R.; Feldman, E.; Heber, D.; Nixon, D.; Picciano, M.F.; Rivlin, R.; Simopoulos, A.; Wargovich, M.J.; Weisburger, E.K.; Zeisel, S.H. The role of dietary supplements during cancer therapy. J. Nutr.,  2003, 133(11)(Suppl. 1), 3794S-3799S.
 [http://dx.doi.org/10.1093/jn/133.11.3794S] [PMID: 14608116]

[35]
Messina, M.J.; Loprinzi, C.L. Soy for breast cancer survivors: A critical review of the literature. J. Nutr.,  2001, 131(11), 3095S-3108S.
 [http://dx.doi.org/10.1093/jn/131.11.3095S] [PMID: 11694655]

[36]
Finkeldey, L.; Schmitz, E.; Ellinger, S. Effect of the intake of isoflavones on risk factors of breast cancer-a systematic review of randomized controlled intervention studies. Nutrients,  2021, 13(7), 2309.
 [http://dx.doi.org/10.3390/nu13072309] [PMID: 34371819]

[37]
Simopoulos, A.P. The Mediterranean diets: What is so special about the diet of Greece? The scientific evidence. J. Nutr.,  2001, 131(11), 3065S-3073S.
 [http://dx.doi.org/10.1093/jn/131.11.3065S] [PMID: 11694649]

[38]
Boisselier, P.; Kaminsky, M-C.; Thézenas, S.; Gallocher, O.; Lavau-Denes, S.; Garcia-Ramirez, M.; Alfonsi, M.; Cupissol, D.; de Forges, H.; Janiszewski, C.; Geoffrois, L.; Sire, C.; Senesse, P. A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX. Am. J. Clin. Nutr.,  2020, 112(6), 1523-1531.
 [http://dx.doi.org/10.1093/ajcn/nqaa227] [PMID: 32936874]

[39]
Staff, N.P.; Cavaletti, G.; Islam, B.; Lustberg, M.; Psimaras, D.; Tamburin, S. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. J. Peripher. Nerv. Syst.,  2019, 24(S2), S26-S39.
 [http://dx.doi.org/10.1111/jns.12335] [PMID: 31647151]

[40]
Chiorazzi, A.; Semperboni, S.; Marmiroli, P. Current view in platinum drug mechanisms of peripheral neurotoxicity. Toxics,  2015, 3(3), 304-321.
 [http://dx.doi.org/10.3390/toxics3030304] [PMID: 29051466]

[41]
Kagiava, A.; Theophilidis, G.; Sargiannidou, I.; Kyriacou, K.; Kleopa, K.A. Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanol. Neuropharmacology,  2015, 97, 289-305.
 [http://dx.doi.org/10.1016/j.neuropharm.2015.05.021] [PMID: 26044641]

[42]
Park, S.B.; Lin, C.S-Y.; Krishnan, A.V.; Goldstein, D.; Friedlander, M.L.; Kiernan, M.C. Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy. Brain,  2009, 132(Pt 10), 2712-2723.
 [http://dx.doi.org/10.1093/brain/awp219] [PMID: 19745023]

[43]
Park, S.B.; Goldstein, D.; Krishnan, A.V.; Lin, C.S-Y.; Friedlander, M.L.; Cassidy, J.; Koltzenburg, M.; Kiernan, M.C. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J. Clin.,  2013, 63(6), 419-437.
 [http://dx.doi.org/10.3322/caac.21204] [PMID: 24590861]

[44]
Roelofs, R.I.; Hrushesky, W.; Rogin, J.; Rosenberg, L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology,  1984, 34(7), 934-938.
 [http://dx.doi.org/10.1212/WNL.34.7.934] [PMID: 6330613]

[45]
Suarez, G.A.; Giannini, C.; Smith, B.E.; Windebank, A.J.; Litchy, W.J.; Dyck, P.J. Localized hypertrophic neuropathy. Mayo Clin. Proc.,  1994, 69(8), 747-748.
 [http://dx.doi.org/10.1016/S0025-6196(12)61093-3] [PMID: 8035630]

[46]
Argyriou, A.A.; Chroni, E.; Koutras, A.; Iconomou, G.; Papapetropoulos, S.; Polychronopoulos, P.; Kalofonos, H.P. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: Final results. Support. Care Cancer,  2006, 14(11), 1134-1140.
 [http://dx.doi.org/10.1007/s00520-006-0072-3] [PMID: 16622646]

[47]
Albers, J.W.; Chaudhry, V.; Cavaletti, G.; Donehower, R.C. Interventions for preventing neuropathy caused by Cisplatin and related compounds. Cochrane Database Syst. Rev.,  2011, 3, CD005228.
 [http://dx.doi.org/10.1002/14651858.CD005228.pub3]

[48]
Schloss, J.M.; Colosimo, M.; Airey, C.; Masci, P.P.; Linnane, A.W.; Vitetta, L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review. Clin. Nutr.,  2013, 32(6), 888-893.
 [http://dx.doi.org/10.1016/j.clnu.2013.04.007] [PMID: 23647723]

[49]
Salehi, Z.; Roayaei, M. Effect of Vitamin E on Oxaliplatin-induced peripheral neuropathy prevention: A randomized controlled trial. Int. J. Prev. Med.,  2015, 6(1), 104.
 [http://dx.doi.org/10.4103/2008-7802.169021] [PMID: 26682028]

[50]
Zoneddy Dayao, M.D. A Randomized phase III study of vitamins B6 and B12 to prevent chemotherapy-induced neuropathy in cancer patients.  NCT00659269 2016.  https://clinicaltrials.gov/ct2/show/results/NCT00659269

[51]
Miao, H.; Li, R.; Chen, D.; Hu, J.; Chen, Y.; Xu, C.; Wen, Z. Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: A meta-analysis of randomized controlled trials. Ann. Nutr. Metab.,  2021, 77(3), 127-137.
 [http://dx.doi.org/10.1159/000515620] [PMID: 34148036]

[52]
Leonetti, C.; Biroccio, A.; Gabellini, C.; Scarsella, M.; Maresca, V.; Flori, E.; Bove, L.; Pace, A.; Stoppacciaro, A.; Zupi, G.; Cognetti, F.; Picardo, M. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int. J. Cancer,  2003, 104(2), 243-250.
 [http://dx.doi.org/10.1002/ijc.10933] [PMID: 12569582]

[53]
Pace, A.; Savarese, A.; Picardo, M.; Maresca, V.; Pacetti, U.; Del Monte, G.; Biroccio, A.; Leonetti, C.; Jandolo, B.; Cognetti, F.; Bove, L. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J. Clin. Oncol.,  2003, 21(5), 927-931.
 [http://dx.doi.org/10.1200/JCO.2003.05.139] [PMID: 12610195]

[54]
Brigelius-Flohé, R.; Kelly, F.J.; Salonen, J.T.; Neuzil, J.; Zingg, J-M.; Azzi, A. The European perspective on vitamin E: Current knowledge and future research. Am. J. Clin. Nutr.,  2002, 76(4), 703-716.
 [http://dx.doi.org/10.1093/ajcn/76.4.703] [PMID: 12324281]

[55]
Kalkanis, J.G.; Whitworth, C.; Rybak, L.P.; Vitamin, E. Vitamin E reduces cisplatin ototoxicity. Laryngoscope,  2004, 114(3), 538-542.
 [http://dx.doi.org/10.1097/00005537-200403000-00028] [PMID: 15091231]

[56]
Granados-Principal, S.; Quiles, J.L.; Ramirez-Tortosa, C.L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M.C. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem. Toxicol.,  2010, 48(6), 1425-1438.
 [http://dx.doi.org/10.1016/j.fct.2010.04.007] [PMID: 20385199]

[57]
Alberts, D.S.; Noel, J.K. Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs,  1995, 6(3), 369-383.
 [http://dx.doi.org/10.1097/00001813-199506000-00003] [PMID: 7670134]

[58]
Satya-Murti, S.; Howard, L.; Krohel, G.; Wolf, B. The spectrum of neurologic disorder from vitamin E deficiency. Neurology,  1986, 36(7), 917-921.
 [http://dx.doi.org/10.1212/WNL.36.7.917] [PMID: 3714053]

[59]
Traber, M.G.; Sokol, R.J.; Ringel, S.P.; Neville, H.E.; Thellman, C.A.; Kayden, H.J. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N. Engl. J. Med.,  1987, 317(5), 262-265.
 [http://dx.doi.org/10.1056/NEJM198707303170502] [PMID: 3037372]

[60]
Pace, A.; Giannarelli, D.; Galiè, E.; Savarese, A.; Carpano, S.; Della Giulia, M.; Pozzi, A.; Silvani, A.; Gaviani, P.; Scaioli, V.; Jandolo, B.; Bove, L.; Cognetti, F.; Vitamin, E. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology,  2010, 74(9), 762-766.
 [http://dx.doi.org/10.1212/WNL.0b013e3181d5279e] [PMID: 20194916]

[61]
Kottschade, L.A.; Sloan, J.A.; Mazurczak, M.A.; Johnson, D.B.; Murphy, B.P.; Rowland, K.M.; Smith, D.A.; Berg, A.R.; Stella, P.J.; Loprinzi, C.L. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support. Care Cancer,  2011, 19(11), 1769-1777.
 [http://dx.doi.org/10.1007/s00520-010-1018-3] [PMID: 20936417]

[62]
Arrieta, Ó.; Hernández-Pedro, N.; Fernández-González-Aragón, M.C.; Saavedra-Pérez, D.; Campos-Parra, A.D.; Ríos-Trejo, M.Á.; Cerón-Lizárraga, T.; Martínez-Barrera, L.; Pineda, B.; Ordóñez, G.; Ortiz-Plata, A.; Granados-Soto, V.; Sotelo, J. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology,  2011, 77(10), 987-995.
 [http://dx.doi.org/10.1212/WNL.0b013e31822e045c] [PMID: 21865574]

[63]
Guo, Y.; Jones, D.; Palmer, J.L.; Forman, A.; Dakhil, S.R.; Velasco, M.R.; Weiss, M.; Gilman, P.; Mills, G.M.; Noga, S.J.; Eng, C.; Overman, M.J.; Fisch, M.J. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Support. Care Cancer,  2014, 22(5), 1223-1231.
 [http://dx.doi.org/10.1007/s00520-013-2075-1] [PMID: 24362907]

[64]
Gedlicka, C.; Scheithauer, W.; Schüll, B.; Kornek, G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J. Clin. Oncol.,  2002, 20(15), 3359-3361.
 [http://dx.doi.org/10.1200/JCO.2002.99.502] [PMID: 12149316]

[65]
Gedlicka, C.; Kornek, G.V.; Schmid, K.; Scheithauer, W. Amelioration of docetaxel/cisplatin induced polyneuropathy by α-lipoic acid. Ann. Oncol.,  2003, 14(2), 339-340.
 [http://dx.doi.org/10.1093/annonc/mdg051] [PMID: 12562664]

[66]
Cascella, M.; Muzio, M.R. Pharmacological approaches and natural products for prevention of chemotherapy-induced peripheral neuropathy - a review. Int. J. Pharmacol. Phytochem. Ethnomed.,  2017, 6, 47-53.
 [http://dx.doi.org/10.18052/www.scipress.com/IJPPE.6.47]

[67]
Nishioka, M.; Shimada, M.; Kurita, N.; Iwata, T.; Morimoto, S.; Yoshikawa, K.; Higashijima, J.; Miyatani, T.; Kono, T. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int. J. Clin. Oncol.,  2011, 16(4), 322-327.
 [http://dx.doi.org/10.1007/s10147-010-0183-1] [PMID: 21258836]

[68]
Kono, T.; Hata, T.; Morita, S.; Munemoto, Y.; Matsui, T.; Kojima, H.; Takemoto, H.; Fukunaga, M.; Nagata, N.; Shimada, M.; Sakamoto, J.; Mishima, H. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother. Pharmacol.,  2013, 72(6), 1283-1290.
 [http://dx.doi.org/10.1007/s00280-013-2306-7] [PMID: 24121454]

[69]
Oki, E.; Emi, Y.; Kojima, H.; Higashijima, J.; Kato, T.; Miyake, Y.; Kon, M.; Ogata, Y.; Takahashi, K.; Ishida, H.; Saeki, H.; Sakaguchi, Y.; Yamanaka, T.; Kono, T.; Tomita, N.; Baba, H.; Shirabe, K.; Kakeji, Y.; Maehara, Y. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): A placebo-controlled, double-blind, randomized phase III study. Int. J. Clin. Oncol.,  2015, 20(4), 767-775.
 [http://dx.doi.org/10.1007/s10147-015-0784-9] [PMID: 25627820]

[70]
Kweekel, D.M.; Gelderblom, H.; Guchelaar, H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev.,  2005, 31(2), 90-105.
 [http://dx.doi.org/10.1016/j.ctrv.2004.12.006] [PMID: 15847979]

[71]
Weickhardt, A.; Wells, K.; Messersmith, W. Oxaliplatin-induced neuropathy in colorectal cancer. J. Oncol.,  2011, 2011, 201593.
 [http://dx.doi.org/10.1155/2011/201593] [PMID: 22203844]

[72]
Gamelin, L.; Boisdron-Celle, M.; Delva, R.; Guérin-Meyer, V.; Ifrah, N.; Morel, A.; Gamelin, E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res.,  2004, 10(12 Pt 1), 4055-4061.
 [http://dx.doi.org/10.1158/1078-0432.CCR-03-0666] [PMID: 15217938]

[73]
Loprinzi, C.L.; Qin, R.; Dakhil, S.R.; Fehrenbacher, L.; Flynn, K.A.; Atherton, P.; Seisler, D.; Qamar, R.; Lewis, G.C.; Grothey, A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J. Clin. Oncol.,  2014, 32(10), 997-1005.
 [http://dx.doi.org/10.1200/JCO.2013.52.0536] [PMID: 24297951]

[74]
Rybak, L.P.; Whitworth, C.A. Ototoxicity: Therapeutic opportunities. Drug Discov. Today,  2005, 10(19), 1313-1321.
 [http://dx.doi.org/10.1016/S1359-6446(05)03552-X] [PMID: 16214676]

[75]
Dehne, N.; Lautermann, J.; Petrat, F.; Rauen, U.; de Groot, H. Cisplatin ototoxicity: Involvement of iron and enhanced formation of superoxide anion radicals. Toxicol. Appl. Pharmacol.,  2001, 174(1), 27-34.
 [http://dx.doi.org/10.1006/taap.2001.9171] [PMID: 11437646]

[76]
Ding, D.; Allman, B.L.; Salvi, R. Review: Ototoxic characteristics of platinum antitumor drugs. Anat. Rec. (Hoboken),  2012, 295(11), 1851-1867.
 [http://dx.doi.org/10.1002/ar.22577] [PMID: 23044998]

[77]
Yu, D.; Gu, J.; Chen, Y.; Kang, W.; Wang, X.; Wu, H. Current strategies to combat Cisplatin-induced ototoxicity. Front. Pharmacol.,  2020, 11, 999.
 [http://dx.doi.org/10.3389/fphar.2020.00999] [PMID: 32719605]

[78]
Scasso, F.; Sprio, A.E.; Canobbio, L.; Scanarotti, C.; Manini, G.; Berta, G.N.; Bassi, A.M. Dietary supplementation of coenzyme Q10 plus multivitamins to hamper the ROS mediated cisplatin ototoxicity in humans: A pilot study. Heliyon,  2017, 3(2), e00251.
 [http://dx.doi.org/10.1016/j.heliyon.2017.e00251] [PMID: 28239674]

[79]
Villani, V.; Zucchella, C.; Cristalli, G.; Galiè, E.; Bianco, F.; Giannarelli, D.; Carpano, S.; Spriano, G.; Pace, A.; Vitamin, E. Neuroprotection against Cisplatin Ototoxicity: Preliminary results from a randomized, placebo-controlled trial: Vitamin E in ototoxicity. Head Neck,  2016, 38(S1), E2118-E2121.
 [http://dx.doi.org/10.1002/hed.24396] [PMID: 26849799]

[80]
Weijl, N.I.; Elsendoorn, T.J.; Lentjes, E.G.W.M.; Hopman, G.D.; Wipkink-Bakker, A.; Zwinderman, A.H.; Cleton, F.J.; Osanto, S. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur. J. Cancer,  2004, 40(11), 1713-1723.
 [http://dx.doi.org/10.1016/j.ejca.2004.02.029] [PMID: 15251161]

[81]
Sarafraz, Z.; Ahmadi, A.; Daneshi, A. Transtympanic injections of N-acetylcysteine and Dexamethasone for prevention of Cisplatin-induced Ototoxicity: Double blind randomized clinical trial. Int. Tinnitus J.,  2018, 22(1), 40-45.
 [http://dx.doi.org/10.5935/0946-5448.20180007] [PMID: 29993216]

[82]
Yıldırım, M.; Inançlı, H.M.; Samancı, B.; Oktay, M.F.; Enöz, M.; Topçu, I. Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate. Kulak Burun Bogaz Ihtis. Derg.,  2010, 20(4), 173-183.
 [PMID: 20626325]

[83]
Abdelsalam, M.; Elmorsy, E.; Abdelwahab, H.; Algohary, O.; Naguib, M.; El Wahab, A.A.; Eldeeb, A.; Eltoraby, E.; Abdelsalam, A.; Sabry, A.; El-Metwally, M.; Akl, M.; Anber, N.; El Sayed Zaki, M.; Almutairi, F.; Mansour, T. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity. BMC Nephrol.,  2018, 19(1), 219.
 [http://dx.doi.org/10.1186/s12882-018-1022-2] [PMID: 30180818]

[84]
Labaye, J.; Sarret, D.; Duvic, C.; Hérody, M.; Didelot, F.; Nédélec, G.; Noël, L-H. Renal toxicity of oxaliplatin. Nephrol. Dial. Transplant.,  2005, 20(6), 1275-1276.
 [http://dx.doi.org/10.1093/ndt/gfh826] [PMID: 15827046]

[85]
Ulusakarya, A.; Misra, S.; Haydar, M.; Habert, H.; Castagne, V.; Gumus, Y.; Delmas-Marsalet, B.; Machover, D. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med. Oncol.,  2010, 27(4), 1425-1426.
 [http://dx.doi.org/10.1007/s12032-009-9263-3] [PMID: 19565364]

[86]
Joybari, A.Y.; Sarbaz, S.; Azadeh, P.; Mirafsharieh, S.A.; Rahbari, A.; Farasatinasab, M.; Mokhtari, M. Oxaliplatin-induced renal tubular vacuolization. Ann. Pharmacother.,  2014, 48(6), 796-800.
 [http://dx.doi.org/10.1177/1060028014526160] [PMID: 24615628]

[87]
Kociba, R.J.; Sleight, S.D. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep.,  1971, 55(1), 1-8.
 [PMID: 5121647]

[88]
Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel),  2010, 2(11), 2490-2518.
 [http://dx.doi.org/10.3390/toxins2112490] [PMID: 22069563]

[89]
Volarevic, V.; Djokovic, B.; Jankovic, M.G.; Harrell, C.R.; Fellabaum, C.; Djonov, V.; Arsenijevic, N. Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci.,  2019, 26(1), 25.
 [http://dx.doi.org/10.1186/s12929-019-0518-9] [PMID: 30866950]

[90]
Ali, B.H.; Al Moundhri, M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem. Toxicol.,  2006, 44(8), 1173-1183.
 [http://dx.doi.org/10.1016/j.fct.2006.01.013] [PMID: 16530908]

[91]
Ma, N.; Wei, W.; Fan, X.; Ci, X. Farrerol attenuates Cisplatin-Induced Nephrotoxicity by inhibiting the reactive oxygen species-mediated oxidation, inflammation, and apoptotic signaling pathways. Front. Physiol.,  2019, 10, 1419.
 [http://dx.doi.org/10.3389/fphys.2019.01419] [PMID: 31849693]

[92]
Ma, P.; Zhang, S.; Su, X.; Qiu, G.; Wu, Z. Protective effects of icariin on cisplatin-induced acute renal injury in mice. Am. J. Transl. Res.,  2015, 7(10), 2105-2114.
 [PMID: 26692955]

[93]
Peres, L.A.B.; da Cunha, A.D., Jr. Acute nephrotoxicity of cisplatin: Molecular mechanisms. J. Bras. Nefrol.,  2013, 35(4), 332-340.
 [http://dx.doi.org/10.5935/0101-2800.20130052] [PMID: 24402113]

[94]
Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstädt, H.; Lanvers-Kaminsky, C.; am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; Koepsell, H.; Jürgens, H.; Schlatter, E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol.,  2010, 176(3), 1169-1180.
 [http://dx.doi.org/10.2353/ajpath.2010.090610] [PMID: 20110413]

[95]
Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol.,  2010, 80(11), 1762-1767.
 [http://dx.doi.org/10.1016/j.bcp.2010.08.019] [PMID: 20813096]

[96]
Nematbakhsh, M.; Ebrahimian, S.; Tooyserkani, M.; Eshraghi-Jazi, F.; Talebi, A.; Ashrafi, F. Gender difference in Cisplatin-induced nephrotoxicity in a rat model: Greater intensity of damage in male than female. Nephrourol. Mon.,  2013, 5(3), 818-821.
 [http://dx.doi.org/10.5812/numonthly.10128] [PMID: 24282792]

[97]
Muraki, K.; Koyama, R.; Honma, Y.; Yagishita, S.; Shukuya, T.; Ohashi, R.; Takahashi, F.; Kido, K.; Iwakami, S.; Sasaki, S.; Iwase, A.; Takahashi, K. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J. Thorac. Dis.,  2012, 4(6), 562-568.
 [PMID: 23205279]

[98]
Oka, T.; Kimura, T.; Suzumura, T.; Yoshimoto, N.; Nakai, T.; Yamamoto, N.; Matsuura, K.; Mitsuoka, S.; Yoshimura, N.; Kudoh, S.; Hirata, K. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: A toxicity study. BMC Pharmacol. Toxicol.,  2014, 15(1), 70.
 [http://dx.doi.org/10.1186/2050-6511-15-70] [PMID: 25472655]

[99]
Yamamoto, Y.; Watanabe, K.; Tsukiyama, I.; Matsushita, H.; Yabushita, H.; Matsuura, K.; Wakatsuki, A. Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin. Anticancer Res.,  2015, 35(4), 2199-2204.
 [PMID: 25862878]

[100]
Katsuda, H.; Yamashita, M.; Katsura, H.; Yu, J.; Waki, Y.; Nagata, N.; Sai, Y.; Miyamoto, K. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull.,  2010, 33(11), 1867-1871.
 [http://dx.doi.org/10.1248/bpb.33.1867] [PMID: 21048313]

[101]
Corbin, M.; Bossaer, J.B. Mannitol prescribing practices with cisplatin before and after an educational newsletter intervention. Hosp. Pharm.,  2017, 52(5), 353-356.
 [http://dx.doi.org/10.1177/0018578717715356] [PMID: 28804151]

[102]
Hägerström, E.; Lindberg, L.; Bentzen, J.; Brødbæk, K.; Zerahn, B.; Kristensen, B. The nephroprotective effect of mannitol in head and neck cancer patients receiving cisplatin therapy. Clin. Med. Insights Oncol.,  2019, 13, 1179554918821320.
 [http://dx.doi.org/10.1177/1179554918821320] [PMID: 30670924]

[103]
Williams, R.P., Jr; Ferlas, B.W.; Morales, P.C.; Kurtzweil, A.J. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J. Oncol. Pharm. Pract.,  2017, 23(6), 422-428.
 [http://dx.doi.org/10.1177/1078155216656927] [PMID: 27352615]

[104]
McKibbin, T.; Cheng, L.L.; Kim, S.; Steuer, C.E.; Owonikoko, T.K.; Khuri, F.R.; Shin, D.M.; Saba, N.F. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support. Care Cancer,  2016, 24(4), 1789-1793.
 [http://dx.doi.org/10.1007/s00520-015-2978-0] [PMID: 26446698]

[105]
Li, S.; He, X.; Ruan, L.; Ye, T.; Wen, Y.; Song, Z.; Hu, S.; Chen, Y.; Peng, B.; Li, S. Protective effect of mannitol on cisplatin-induced nephrotoxicity: A systematic review and meta-analysis. Front. Oncol.,  2021, 11, 804685.
 [http://dx.doi.org/10.3389/fonc.2021.804685] [PMID: 34976843]

[106]
Minzi, O.M.S.; Lyimo, T.E.; Furia, F.F.; Marealle, A.I.; Kilonzi, M.; Bwire, G.M.; Malichewe, C. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol. Toxicol.,  2020, 21(1), 69.
 [http://dx.doi.org/10.1186/s40360-020-00448-9] [PMID: 32967726]

[107]
Mahmoodnia, L.; Mohammadi, K.; Masumi, R. Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient. J. Nephropathol.,  2017, 6(3), 144-149.
 [http://dx.doi.org/10.15171/jnp.2017.25] [PMID: 28975094]

[108]
Nasiri, M.; Farhangi, H.; Badee, Z.; Ghasemi, A.; Golsorkhi, M.; Ravanshad, Y.; Azarfar, A. The effect of Vitamin E on Cisplatin induced nephrotoxicity: A clinical trial study. Int. J. Pediatr.,  2020, 8(1), 10767-10773.
 [http://dx.doi.org/10.22038/ijp.2019.42813.3656]

[109]
Lobb, R.J.; Jacobson, G.M.; Cursons, R.T.; Jameson, M.B. The Interaction of selenium with chemotherapy and radiation on normal and malignant human mononuclear blood cells. Int. J. Mol. Sci.,  2018, 19(10), 3167.
 [http://dx.doi.org/10.3390/ijms19103167] [PMID: 30326581]

[110]
Ghorbani, A.; Omidvar, B.; Parsi, A. Protective effect of selenium on cisplatin induced nephrotoxicity: A double-blind controlled randomized clinical trial. J. Nephropathol.,  2013, 2(2), 129-134.
 [http://dx.doi.org/10.5812/nephropathol.10656] [PMID: 24475439]

[111]
Nematbakhsh, M.; Nasri, H. The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: A randomized, placebo-controlled study. J. Res. Med. Sci.,  2013, 18(7), 626-627.
 [PMID: 24516499]

[112]
Di Fiore, F.; Van Cutsem, E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract. Res. Clin. Gastroenterol.,  2009, 23(1), 113-124.
 [http://dx.doi.org/10.1016/j.bpg.2008.11.016] [PMID: 19258191]

[113]
Xue, H.; Sawyer, M.B.; Wischmeyer, P.E.; Baracos, V.E. Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: From preclinical findings to clinical strategy. JPEN J. Parenter. Enteral Nutr.,  2011, 35(1), 74-90.
 [http://dx.doi.org/10.1177/0148607110377338] [PMID: 21224434]

[114]
Gralla, R.J.; Itri, L.M.; Pisko, S.E.; Squillante, A.E.; Kelsen, D.P.; Braun, D.W., Jr; Bordin, L.A.; Braun, T.J.; Young, C.W. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med.,  1981, 305(16), 905-909.
 [http://dx.doi.org/10.1056/NEJM198110153051601] [PMID: 7024807]

[115]
Bloechl-Daum, B.; Deuson, R.R.; Mavros, P.; Hansen, M.; Herrstedt, J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol.,  2006, 24(27), 4472-4478.
 [http://dx.doi.org/10.1200/JCO.2006.05.6382] [PMID: 16983116]

[116]
Lete, I.; Allué, J. The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy. Integr. Med. Insights,  2016, 11, 11-17.
 [http://dx.doi.org/10.4137/IMI.S36273] [PMID: 27053918]

[117]
Lee, J.; Oh, H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Oncol. Nurs. Forum,  2013, 40(2), 163-170.
 [http://dx.doi.org/10.1188/13.ONF.163-170] [PMID: 23448741]

[118]
Marx, W.M.; Teleni, L.; McCarthy, A.L.; Vitetta, L.; McKavanagh, D.; Thomson, D.; Isenring, E. Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: A systematic literature review. Nutr. Rev.,  2013, 71(4), 245-254.
 [http://dx.doi.org/10.1111/nure.12016] [PMID: 23550785]

[119]
Jordan, K.; Gralla, R.; Jahn, F.; Molassiotis, A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur. J. Pharmacol.,  2014, 722, 197-202.
 [http://dx.doi.org/10.1016/j.ejphar.2013.09.073] [PMID: 24157984]

[120]
Bossi, P.; Cortinovis, D.; Fatigoni, S.; Cossu Rocca, M.; Fabi, A.; Seminara, P.; Ripamonti, C.; Alfieri, S.; Granata, R.; Bergamini, C.; Agustoni, F.; Bidoli, P.; Nolè, F.; Pessi, M.A.; Macchi, F.; Michellini, L.; Montanaro, F.; Roila, F. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann. Oncol.,  2017, 28(10), 2547-2551.
 [http://dx.doi.org/10.1093/annonc/mdx315] [PMID: 28666335]

[121]
Li, X.; Qin, Y.; Liu, W.; Zhou, X.Y.; Li, Y.N.; Wang, L.Y. Efficacy of ginger in ameliorating acute and delayed chemotherapy-induced nausea and vomiting among patients with lung cancer receiving cisplatin-based regimens: A randomized controlled trial. Integr. Cancer Ther.,  2018, 17(3), 747-754.
 [http://dx.doi.org/10.1177/1534735417753541] [PMID: 29417850]

[122]
Pillai, A.K.; Sharma, K.K.; Gupta, Y.K.; Bakhshi, S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr. Blood Cancer,  2011, 56(2), 234-238.
 [http://dx.doi.org/10.1002/pbc.22778] [PMID: 20842754]

[123]
Giacosa, A.; Morazzoni, P.; Bombardelli, E.; Riva, A.; Bianchi Porro, G.; Rondanelli, M. Can nausea and vomiting be treated with ginger extract? Eur. Rev. Med. Pharmacol. Sci.,  2015, 19(7), 1291-1296.
 [PMID: 25912592]

[124]
Schwertner, H.A.; Rios, D.C. High-performance liquid chromatographic analysis of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol in ginger-containing dietary supplements, spices, teas, and beverages. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2007, 856(1-2), 41-47.
 [http://dx.doi.org/10.1016/j.jchromb.2007.05.011] [PMID: 17561453]

[125]
Mogami, S.; Hattori, T. Beneficial effects of rikkunshito, a Japanese kampo medicine, on gastrointestinal dysfunction and anorexia in combination with Western drug: A systematic review. Evid. Based Complement. Alternat. Med.,  2014, 2014, 519035.
 [http://dx.doi.org/10.1155/2014/519035] [PMID: 24778703]

[126]
Takeda, H.; Sadakane, C.; Hattori, T.; Katsurada, T.; Ohkawara, T.; Nagai, K.; Asaka, M. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology,  2008, 134(7), 2004-2013.
 [http://dx.doi.org/10.1053/j.gastro.2008.02.078] [PMID: 18439428]

[127]
Ohnishi, S.; Watari, H.; Kanno, M.; Ohba, Y.; Takeuchi, S.; Miyaji, T.; Oyamada, S.; Nomura, E.; Kato, H.; Sugiyama, T.; Asaka, M.; Sakuragi, N.; Yamaguchi, T.; Uezono, Y.; Iwase, S. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: Results of a Randomized Phase II Study (JORTC KMP-02). J. Gynecol. Oncol,  2017, 28(5), e44.
 [http://dx.doi.org/10.3802/jgo.2017.28.e44]

[128]
Ohnishi, S.; Ariyoshi, K.; Oyamada, S.; Kihara, K.; Konno, Y.; Watari, H. A protocol for efficacy of rikkunshito on chemotherapy-induced nausea and vomiting in patients with uterine corpus or cervical cancer treated with cisplatin-based regimen-placebo-controlled, double-blind, randomized confirmatory study (efficacy of rikkunshito on chemotherapy-induced nausea and vomiting). Medicine,  2021, 2(6), e0109.
 [http://dx.doi.org/10.1097/MD9.0000000000000109]

[129]
Inoue, T.; Takagi, H.; Owada, Y.; Watanabe, Y.; Yamaura, T.; Fukuhara, M.; Muto, S.; Okabe, N.; Matsumura, Y.; Hasegawa, T.; Osugi, J.; Hoshino, M.; Higuchi, M.; Shio, Y.; Yokouchi, H.; Kanazawa, K.; Ohbuchi, K.; Fukushima, T.; Munakata, M.; Suzuki, H. The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): Study protocol for a randomized controlled trial. Trials,  2017, 18(1), 485.
 [http://dx.doi.org/10.1186/s13063-017-2227-6] [PMID: 29047408]

[130]
Yoshiya, T.; Mimae, T.; Ito, M.; Sasada, S.; Tsutani, Y.; Satoh, K.; Masuda, T.; Miyata, Y.; Hattori, N.; Okada, M. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. Invest. New Drugs,  2020, 38(2), 485-492.
 [http://dx.doi.org/10.1007/s10637-019-00836-x] [PMID: 31428894]

[131]
Hamai, Y.; Yoshiya, T.; Hihara, J.; Emi, M.; Furukawa, T.; Yamakita, I.; Ibuki, Y.; Okada, M. Traditional Japanese herbal medicine rikkunshito increases food intake and plasma acylated ghrelin levels in patients with esophageal cancer treated by cisplatin-based chemotherapy. J. Thorac. Dis.,  2019, 11(6), 2470-2478.
 [http://dx.doi.org/10.21037/jtd.2019.05.67] [PMID: 31372284]

[132]
Fouladbakhsh, J.M.; Balneaves, L.; Jenuwine, E. Understanding CAM natural health products: Implications of use among cancer patients and survivors. J. Adv. Pract. Oncol.,  2013, 4(5), 289-306.
 [http://dx.doi.org/10.6004/jadpro.2013.4.5.2] [PMID: 25032009]

[133]
Asher, G.N.; Corbett, A.H.; Hawke, R.L. Common herbal dietary supplement-drug interactions. Am. Fam. Physician,  2017, 96(2), 101-107.
 [PMID: 28762712]

[134]
Dizdar, O.; Bilgin, E.; Akin, S.; Kilickap, S.; Hayran, M. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database. J. BUON,  2017, 22(2), 530-534.
 [PMID: 28534381]

[135]
Andersen, M.R.; Sweet, E.; Lowe, K.A.; Standish, L.J.; Drescher, C.W.; Goff, B.A. Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J. Altern. Complement. Med.,  2013, 19(8), 714-720.
 [http://dx.doi.org/10.1089/acm.2012.0295] [PMID: 23445210]

[136]
Heaney, M.L.; Gardner, J.R.; Karasavvas, N.; Golde, D.W.; Scheinberg, D.A.; Smith, E.A.; O’Connor, O.A.; Vitamin, C. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res.,  2008, 68(19), 8031-8038.
 [http://dx.doi.org/10.1158/0008-5472.CAN-08-1490] [PMID: 18829561]

[137]
Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J. Pharmacol. Exp. Ther.,  2005, 312(2), 424-431.
 [http://dx.doi.org/10.1124/jpet.104.075119] [PMID: 15496615]

[138]
Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther.,  2013, 138(1), 103-141.
 [http://dx.doi.org/10.1016/j.pharmthera.2012.12.007] [PMID: 23333322]

[139]
Alnaim, L. Therapeutic drug monitoring of cancer chemotherapy. J. Oncol. Pharm. Pract.,  2007, 13(4), 207-221.
 [http://dx.doi.org/10.1177/1078155207081133] [PMID: 18045780]

[140]
Ruwali, M.; Khan, A.J.; Shah, P.P.; Singh, A.P.; Pant, M.C.; Parmar, D. Cytochrome P450 2E1 and head and neck cancer: Interaction with genetic and environmental risk factors. Environ. Mol. Mutagen.,  2009, 50(6), 473-482.
 [http://dx.doi.org/10.1002/em.20488] [PMID: 19334053]

[141]
Greenblatt, D.J.; von Moltke, L.L.; Perloff, E.S.; Luo, Y.; Harmatz, J.S.; Zinny, M.A. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies. Clin. Pharmacol. Ther.,  2006, 79(1), 125-133.
 [http://dx.doi.org/10.1016/j.clpt.2005.09.014] [PMID: 16413247]

[142]
Kimura, Y.; Ito, H.; Ohnishi, R.; Hatano, T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem. Toxicol.,  2010, 48(1), 429-435.
 [http://dx.doi.org/10.1016/j.fct.2009.10.041] [PMID: 19883715]

[143]
Ngo, N.; Yan, Z.; Graf, T.N.; Carrizosa, D.R.; Kashuba, A.D.M.; Dees, E.C.; Oberlies, N.H.; Paine, M.F. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab. Dispos.,  2009, 37(3), 514-522.
 [http://dx.doi.org/10.1124/dmd.108.024968] [PMID: 19114462]

[144]
Uesawa, Y.; Mohri, K. Effects of cranberry juice on nifedipine pharmacokinetics in rats. J. Pharm. Pharmacol.,  2006, 58(8), 1067-1072.
 [http://dx.doi.org/10.1211/jpp.58.8.0007] [PMID: 16872553]

[145]
Fasinu, P.S.; Rapp, G.K. Herbal interaction with chemotherapeutic drugs-a focus on clinically significant findings. Front. Oncol.,  2019, 9, 1356.
 [http://dx.doi.org/10.3389/fonc.2019.01356] [PMID: 31850232]

[146]
Gupta, D.; Lis, C.G.; Birdsall, T.C.; Grutsch, J.F. The use of dietary supplements in a community hospital comprehensive cancer center: Implications for conventional cancer care. Support. Care Cancer,  2005, 13(11), 912-919.
 [http://dx.doi.org/10.1007/s00520-005-0820-9] [PMID: 15856334]

[147]
Ambrosone, C.B.; Zirpoli, G.R.; Hutson, A.D.; McCann, W.E.; McCann, S.E.; Barlow, W.E.; Kelly, K.M.; Cannioto, R.; Sucheston-Campbell, L.E.; Hershman, D.L.; Unger, J.M.; Moore, H.C.F.; Stewart, J.A.; Isaacs, C.; Hobday, T.J.; Salim, M.; Hortobagyi, G.N.; Gralow, J.R.; Budd, G.T.; Albain, K.S. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J. Clin. Oncol.,  2020, 38(8), 804-814.
 [http://dx.doi.org/10.1200/JCO.19.01203] [PMID: 31855498]

[148]
Rombolà, L.; Scuteri, D.; Marilisa, S.; Watanabe, C.; Morrone, L.A.; Bagetta, G.; Corasaniti, M.T. Pharmacokinetic interactions between herbal medicines and drugs: Their mechanisms and clinical relevance. Life (Basel),  2020, 10(7), 106.
 [http://dx.doi.org/10.3390/life10070106] [PMID: 32635538]
Cite As
Current Medicinal Chemistry

Clinical Evidence of Interaction between Nutraceutical Supplementation and Platinum-based Chemotherapy

Abstract
